341 related articles for article (PubMed ID: 29666783)
1. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
Lee AR; Che N; Lovnicki JM; Dong X
Front Oncol; 2018; 8():93. PubMed ID: 29666783
[TBL] [Abstract][Full Text] [Related]
2. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
[TBL] [Abstract][Full Text] [Related]
3. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
4. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
5. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
[TBL] [Abstract][Full Text] [Related]
6. Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.
Gan Y; Li Y; Long Z; Lee AR; Xie N; Lovnicki JM; Tang Y; Chen X; Huang J; Dong X
EBioMedicine; 2018 May; 31():267-275. PubMed ID: 29759485
[TBL] [Abstract][Full Text] [Related]
7. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
[TBL] [Abstract][Full Text] [Related]
8. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
[TBL] [Abstract][Full Text] [Related]
9. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
[TBL] [Abstract][Full Text] [Related]
10. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
[TBL] [Abstract][Full Text] [Related]
12. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.
Li JJ; Vasciaveo A; Karagiannis D; Sun Z; Chen X; Socciarelli F; Frankenstein Z; Zou M; Pannellini T; Chen Y; Gardner K; Robinson BD; de Bono J; Abate-Shen C; Rubin MA; Loda M; Sawyers CL; Califano A; Lu C; Shen MM
bioRxiv; 2023 Jul; ():. PubMed ID: 37502956
[TBL] [Abstract][Full Text] [Related]
13. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
15. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
16. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Beltran H; Prandi D; Mosquera JM; Benelli M; Puca L; Cyrta J; Marotz C; Giannopoulou E; Chakravarthi BV; Varambally S; Tomlins SA; Nanus DM; Tagawa ST; Van Allen EM; Elemento O; Sboner A; Garraway LA; Rubin MA; Demichelis F
Nat Med; 2016 Mar; 22(3):298-305. PubMed ID: 26855148
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming landscape highlighted by dynamic transcriptomes in therapy-induced neuroendocrine differentiation.
Asberry AM; Liu S; Nam HS; Deng X; Wan J; Hu CD
Comput Struct Biotechnol J; 2022; 20():5873-5885. PubMed ID: 36382181
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
[TBL] [Abstract][Full Text] [Related]
19. An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.
Yoshida M; Oda C; Mishima K; Tsuji I; Obika S; Shimojo M
Cancer Cell Int; 2023 Jan; 23(1):8. PubMed ID: 36650528
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
